Newly Diagnosed
Get started learning about lymphoma

Donate
You can make a real difference

Register or  Log-In
Get e-mail updates on what's important to you


Charity Navigator
Best in America
Printer Friendly Page

Lymphoma Research Foundation Press Room:

Mantle Cell Lymphoma Alert – High response rate for Lenalidomide
Thomas Habermann, MD, SAB Executive Committee member, discovers that Lenalidomide is well tolerated and active in relapsed or refractory mantle cell lymphoma patients.